Biology subjects

Roerink, S.

Publications and source records attributed to Roerink, S..

3 recordsLinked to original sources

bioRxiv2026

The pan-cancer whole-genome landscape of Adolescent and Young Adult solid cancers

Cancer incidence in adolescents and young adults (AYAs; 18-39 years) is rising, but how their tumors differ genomically from those of older adults (OAs) is unclear. We analyzed paired tumor-normal whole-genomes from 698 AYAs and 5,220 OAs, with subcohorts matched by cancer group to disentangle age from tumor type. AYA tumors carried fewer somatic variants yet largely shared the same genetic drivers; many apparent age differences reflected age-dependent cancer subtypes, such as IDH-mutant glioma and HPV-positive cervical cancer. Colibactin, APOBEC and homologous recombination deficiency-associated signatures were more prevalent in AYA colorectal, gynecological and breast cancers, respectively, but were not more mutagenic when present, suggesting earlier-life activity rather than AYA-specific mutagenesis. Tumor type-concordant pathogenic germline variants were enriched in AYAs (10.9% overall versus 6.6% in matched OAs; p=0.006), often with a somatic second hit. Age thus shaped AYA cancer genomes through mutational processes, subtype composition and germline predisposition, supporting comprehensive tumor-normal profiling beyond driver-focused testing.

cancer biology↗

bioRxiv2025

Systematic identification of genomic non-response biomarkers to cancer therapies

The costs of cancer therapies are rising rapidly across the globe, with novel therapies like targeted treatment and immunotherapies as major contributors, but their effectiveness can be low or uncertain due to limited post market surveillance. Reliable biomarkers to identify patients highly unlikely to respond to cancer therapies represent an increasingly important clinical and societal need, as they could prevent unnecessary treatments, reduce side effects, and alleviate pressure on healthcare systems. Here, we developed a robust statistical framework and applied it to whole-genome and transcriptome sequencing data of cancer patients (n = 2,596) with advanced disease. Our approach systematically identified known and potentially novel genomic and transcriptomic biomarkers of non-response, such as immune evasion driver events in skin melanoma patients treated with anti-PD-1 checkpoint inhibitors, and KRASG12 mutations in metastatic colorectal cancer patients treated with different chemotherapy regimens. Despite the identification of these promising non-response signals, an analytical power analysis revealed that for most treatments and/or cancer types the cohort sizes are underpowered. Our results underscore the promises and the urgent need for expanding response-annotated real-world comprehensive genomics datasets to enable robust biomarker identification and validation.

genomics↗

bioRxiv2022

High-fat diet promotes Acute Promyelocytic Leukemia through PPARδ-enhanced self-renewal of preleukemic progenitors

Obesity is associated with a higher risk of developing many cancer types including acute promyelocytic leukaemia (APL), a subset of acute myeloid leukemias (AML) characterized by expression of the PML-RAR oncogene. The molecular mechanisms linking obesity and APL development are not known. To model clinical observations, we established a mouse model of diet-induced obesity using transgenic mice constitutively expressing PML-RARA in the hematopoietic system (PML-RAR KI mice) fed either standard (SD) or high-fat (HFD) diets. HFD-fed PML-RAR KI mice developed leukaemia with reduced latency and increased penetrance, as compared to SD-fed mice. HFD leads to accumulation of DNA damage in hematopoietic stem cells (HSCs), but, surprisingly, this was not associated with mutational load gain, as shown by whole genome/exome sequencing of pre-leukemic and leukemic cells. Importantly, very few of the observed mutations were predicted to act as cancer drivers, suggesting the relevance of nongenetic mechanisms. HFD led to an expansion of hematopoietic progenitor cells with a concomitant reduction in long-term hematopoietic stem cells, and in the presence of PML-RAR this was also accompanied by an enhancement of in vitro and in vivo self-renewal. Interestingly, Linoleic Acid (LA), abundant in HFD, recapitulates the effect of HFD on the self-renewal of PML-RAR HPCs by activating the peroxisome proliferator-activated receptor delta (PPAR{delta}), a central regulator of fatty acid metabolism involved in the promotion of cancer progression. Our findings have implications for dietary or pharmacological interventions aimed at counteracting the cancer-promoting effect of obesity. Key pointsO_LIhigh fat diet (HFD) promotes APL leukemogenesis in mouse models, reproducing the exquisite sensitivity to obesity observed in humans C_LIO_LIalthough HFD leads to DNA damage and mutations, the molecular mechanism is nongenetic and linked to the transcription factor PPAR{delta} C_LI

cancer biology↗